Business

Pharmalot

Novo Nordisk’s Jorgensen: If it was easy to correct pricing, we would be doing it already

By Ed Silverman

Business

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

By Adam Feuerstein

Biotech

The biotech scorecard for the third quarter: 12 stock-moving events to watch

By Adam Feuerstein

Health

Ex-Theranos CEO Elizabeth Holmes gets a trial date: summer 2020

By Rebecca Robbins

Biotech

How Brent Saunders’ Allergan experiment failed

By Matthew Herper

Biotech

A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage

By Adam Feuerstein

Politics

Consumer genetic testing companies team up to lobby on privacy policy

By Andrew Joseph

Business

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

By Adam Feuerstein and Matthew Herper

Business

PatientsLikeMe, forced by U.S. to ditch Chinese investor, sold to UnitedHealth Group

By Matthew Herper

Business

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

By Jonathan Saltzman — Boston Globe

Politics

VA declines broad coverage for new J&J depression drug touted by Trump

By Lev Facher and Ed Silverman

Pharma

WHO rescinds opioid guidelines following criticism by two U.S. lawmakers

By Priyanka Dayal McCluskey — Boston Globe

Biotech

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

By Adam Feuerstein

Business

Federally funded research drives nearly one-third of U.S. patents, report finds

By Brittany Flaherty

Business

Drug-pricing watchdog group is ‘mouse that roared’

By Jonathan Saltzman — Boston Globe

Health Tech

Webinar: Progress and pitfalls in the AI-aided search for novel drugs

By Casey Ross and Kate Sheridan

Business

Amazon looking to work directly with health plans and employers to sell prescription drugs, court documents say

By Casey Ross

Biotech

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

By Adam Feuerstein

Biotech

Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger

By Adam Feuerstein

Jennifer Doudna - Genome Editing Conference

Exclusive

GSK partners with CRISPR pioneer Doudna to search for new drugs

By Matthew Herper

Pharmalot

As Amazon seeks to win over health care consumers, its PillPack is accused of violating privacy

By Ed Silverman

Biotech

Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

By Adam Feuerstein

Intermountain Medical Center main campus

Business

Intermountain, Amgen subsidiary to launch DNA study of 500,000 patients

By Andrew Joseph

Biotech

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Jacobus price for rare disease drug sets up battle with rival Catalyst; Repatha called cost-effective

By Elizabeth Cooney

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

The Parker Institute looks to grow, leveraging outside donors and equity stakes

Takeda, already a giant in Mass. biopharma, plans a bigger footprint

Stem-cell biotech seeing strong growth

Novo Nordisk’s Jorgensen: If it was easy to correct pricing, we would be doing it already

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

The biotech scorecard for the third quarter: 12 stock-moving events to watch

Ex-Theranos CEO Elizabeth Holmes gets a trial date: summer 2020

How Brent Saunders’ Allergan experiment failed

A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage

Consumer genetic testing companies team up to lobby on privacy policy

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

PatientsLikeMe, forced by U.S. to ditch Chinese investor, sold to UnitedHealth Group

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

VA declines broad coverage for new J&J depression drug touted by Trump

WHO rescinds opioid guidelines following criticism by two U.S. lawmakers

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

Federally funded research drives nearly one-third of U.S. patents, report finds

Drug-pricing watchdog group is ‘mouse that roared’

Webinar: Progress and pitfalls in the AI-aided search for novel drugs

Amazon looking to work directly with health plans and employers to sell prescription drugs, court documents say

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger

GSK partners with CRISPR pioneer Doudna to search for new drugs

As Amazon seeks to win over health care consumers, its PillPack is accused of violating privacy

Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

Intermountain, Amgen subsidiary to launch DNA study of 500,000 patients

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

Pharmalittle: Jacobus price for rare disease drug sets up battle with rival Catalyst; Repatha called cost-effective